|
|
|
|
Vol. 55, Issue 4, 693-698, April 1999
Grace Cancer Drug Center, Roswell Park Cancer Institute (D.L.K., C.W.P), Buffalo, New York; and A.I. Virtanen Institute (L.A., M.H., M.P., J.J.), University of Kuopio, Kuopio, Finland
| |
Summary |
|---|
|
|
|---|
We have recently generated transgenic mice in which polyamine catabolism has been activated by overexpressing the rate-limiting enzyme of polyamine catabolism, spermidine/spermine N1-acetyltransferase (SSAT). These animals have now been tested for their sensitivity to the polyamine analog N1,N11-diethylnorspermine (DENSPM), which is currently undergoing Phase I clinical trial. The analog is known for its ability to potently induce SSAT. Treatment for 4 days with a daily dose (125 mg/kg) of analog caused profound changes in polyamine metabolism in the transgenic animals. Liver SSAT activity was increased by approximately 800-fold while hepatic mRNA increased only 4-fold. Putrescine pools increased while spermidine and spermine pools nearly disappeared, resulting in a compensatory increase in ornithine decarboxylase activity. Similar but less profound changes were also seen in other tissues (spleen, intestine, and skin). This treatment also resulted in a 50% mortality in the transgenic animals, with no apparent histopathological changes in major organs. Nontransgenic animals exhibited no toxicity, and tissue SSAT activity was unchanged or only moderately increased. Polyamine pools were only slightly altered. Greater analog toxicity in transgenic animals may be attributable to higher tissue levels of DENSPM facilitated by SSAT-mediated decreases in spermidine and spermine. To further confirm the enhanced sensitivity of the transgenic animals to the analog, groups of nontransgenic and transgenic animals were subjected to daily injections with DENSPM. On average, transgenic mice died ~3 days earlier than their nontransgenic litter-mates. The findings indicate a contributing role for SSAT in whole animal toxicity by SSAT-inducing polyamine analogs.
| |
Introduction |
|---|
|
|
|---|
The
polyamine biosynthetic pathway has long been considered a worthwhile
target for cancer chemotherapy. However, despite the impressive
preclinical activity of inhibitors of ornithine decarboxylase (ODC),
the rate-controlling enzyme of the biosynthesis, the results of
clinical trials have so far not met expectations (Jänne et al.
1991
; Porter et al. 1992
; Kramer, 1996
). Certain of these inhibitors
are currently being reevaluated as chemopreventive agents (Creaven et
al. 1993
; Love et al. 1993
), and promising results are emerging. On the
basis of impressive preclinical findings (Regenass et al. 1992
, 1994
),
a newly identified inhibitor of another biosynthetic enzyme,
S-adenosylmethionine decarboxylase (AdoMetDC), is now being
evaluated in patients with solid tumors.
Another approach to cancer chemotherapy involves the use of
N-alkylated polyamine analogs to deregulate polyamine
biosynthesis and metabolism. Although initially developed to suppress
the biosynthetic enzymes (Porter and Bergeron, 1988
), subsequent
studies revealed that the antiproliferative action of the analogs may
be more closely linked with a striking activation of polyamine
catabolism and/or excretion (Porter et al. 1992
; Kramer, 1996
).
Polyamine analogs such a
N1,N11-diethylnorspermine
(DENSPM) have been shown to potently induce spermidine/spermine
N1-acetyltransferase (SSAT) (Casero et
al. 1989
; Pegg et al. 1989
; Porter et al. 1991
; Shappell et al., 1992
),
the enzyme that facilitates polyamine export and back-conversion via
oxidative catabolism (Seiler, 1987
). Studies with different human tumor
cell lines (Casero et al. 1989
; Porter et al. 1991
; Casero et al. 1992
;
Shappell et al. 1992
) have revealed a close relationship between the
antiproliferative action and the induction of SSAT. This linkage seems
to be mediated by the depletion of spermidine and spermine, as
facilitated by SSAT, together with the inability of the analog to
substitute for the missing polyamines in functions required for cell
proliferation. Indeed, substantial induction of SSAT without apparent
cytotoxicity can be achieved with various methyl derivatives of
spermine, which seem to be at least partially able to support cell
growth (Yang et al. 1995
; Kramer et al. 1997
).
Very little is known about the consequences of constitutive
overexpression of SSAT. Inducible expression of human SSAT in Escherichia coli apparently results in a reduced growth rate
due to the conversion of all spermidine to
N1-acetylspermidine (Parry et al.
1995b
). The gene has also been transiently expressed in COS
cells, resulting in an enhanced accumulation of putrescine, the
appearance of N1-acetylspermidine, a
decrease in spermidine and spermine pools, and a compensatory increase
in biosynthetic enzyme activities (Vargiu and Persson, 1994
). The fact
that no effects on cell growth were reported is apparently attributable
to the short-term nature of the experiment (Vargiu and Persson, 1994
).
We recently generated a transgenic mouse line that constitutively
overexpressed the murine SSAT gene in all tissues (Pietilä et al.
1997
). Members of the transgenic line showed profound changes in tissue
polyamine pools, including a massive accumulation of putrescine, the
appearance of N1-acetylspermidine, and
a decrease in spermidine and/or spermine pools (Pietilä et al.
1997
). The phenotypic features of the transgenic animals included
permanent hair loss at early age, skin wrinkling, and female
infertility (Pietilä et al. 1997
). In the present study, we have
used these mice to examine the biological and metabolic consequences
resulting from DENSPM induction of SSAT. Subchronic exposure of the
transgenic animals to the drug led to a dramatic increase in SSAT
activity and a near-total depletion of tissue spermidine and spermine
pools, which were clearly related to activated polyamine catabolism.
These changes were associated with greater analog toxicity in the
transgenic animals.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
The spermine analog, DENSPM, was synthesized as
described earlier (Bergeron et al. 1988
, 1989
) and was kindly provided
by Warner Lambert Parke-Davis (Ann Arbor, MI). The drug was dissolved in saline and administered i.p. to mice.
Generation of Transgenic Mice.
The transgenic mice were
generated using the standard pronuclear microinjection technique (Hogan
et al. 1986
). Fertilized oocytes were obtained from BALBc × DBA/2
(CD2F1) females mated with CD2F1 males. The SSAT gene construct used
was an 18-kbp genomic sequence isolated from 129 SVJ mouse genomic
library (Stratagene, La Jolla, CA). The transgene construct contained
all the exons and introns of the murine SSAT gene together with 3 kbp
of the 5'-flanking region (endogenous promoter) and 11.5 kbp of the 3' flanking region. (Pietilä et al. 1997
). Because the transgene was
an endogenous mouse gene, the initial detection of transgenic animals
with polymerase chain reaction was based on simultaneous integration of
multiple transgene copies in the form of concatamers, so that a minimum
of two integrated transgene copies were required for the detection
(Pietilä et al. 1997
). The detection of transgenic pups was later
based on the permanent loss of hair at the age of 3 to 4 weeks.
Transgenic status was also occasionally checked from DNA samples. The
transgenic animals used in this study were members of the line UKU165b,
harboring more than 20 SSAT copies in their genome (Pietilä et
al. 1997
).
Analytical Methods.
Total RNA was extracted with guanidine
isothiocyanate (Chomczynski and Sacchi, 1987
) and purified by CsCl
gradient centrifugation (Ross, 1976
). Human SSAT cDNA probe (Xiao et
al. 1991
) was used in Northern blot analyses. The activities of SSAT,
ODC, and AdoMetDC were assayed as described earlier (Bernacki et al.
1995
). Polyamines, their acetylated derivatives, and DENSPM were
measured by HPLC as described by Kramer et al. (1995)
. The tissue
specimens for histology were fixed in 10% formalin in phosphate
buffer, embedded in paraffin, cut into 5-µm sections, stained with
hematoxylin/eosin, and evaluated microscopically. For statistical
analyses, two-tailed t test was used.
| |
Results |
|---|
|
|
|---|
Effect of a Single Dose of DENSPM on Nontransgenic and SSAT
Transgenic Mice.
We have previously published a detailed analysis
of baseline SSAT mRNA and activities in the various tissues of SSAT
transgenic and nontransgenic animals (Pietilä et al., 1997
). In
an analysis of six tissues, we found that SSAT mRNA levels were
elevated to a greater extent than SSAT activity, suggesting the
existence of feedback regulation by polyamine pools via
post-transcriptional mechanisms. In the present study, we initially
examined the effects of the polyamine analog DENSPM on SSAT mRNA and
activity in transgenic and nontransgenic animals. In a pilot
experiment, mice (two mice in each group) received a single i.p. dose
(100 mg/kg) of DENSPM 24 h before sacrifice. The analog was
well-tolerated by transgenic and nontransgenic animals alike. DENSPM
concentration was approximately 14-fold higher in transgenic liver
(999-1032 pmol/mg tissue) in comparison with nontransgenic. Figure
1 depicts SSAT mRNA and activity from
selected tissues (liver, kidney, brain, and intestine) of nontransgenic
and transgenic animals, untreated or treated with DENSPM. In either
transgenic or nontransgenic animals, the single injection of the analog
did not appear to increase SSAT mRNA levels by more than 2-fold and
actually decreased them slightly (i.e., <30%) in the intestine.
Analog treatment had a similar effect on SSAT activity in the tissues
of nontransgenic animals, while increasing that of transgenic animals
by up to 9.5-fold in the case of the liver, suggesting
post-transcriptional stimulation. Consistent with the latter finding,
the livers of the treated transgenic animals showed distinct signs of
enhanced polyamine catabolism as indicated by a more than 20% decrease
in spermidine and spermine pools and a 2.3-fold increase in putrescine.
A more detailed analysis of analog effects was conducted in mice
receiving multiple doses of analog as follows.
|
Effect of Multiple Doses of DENSPM on Nontransgenic and SSAT Transgenic Mice. Mice were subsequently subjected to daily treatment with higher multiple daily doses (200 mg/kg) of DENSPM. While the nontransgenic animals tolerated DENSPM without signs of toxicity, one of three transgenic animals in the treatment group died on day 3 and the remaining two animals appeared unwell and/or moribund. Thus, although the experiment was designed to involve 5 injections, treatment was terminated 24 h after the third injection. A histological examination of liver, spleen, kidney, heart, brain, skin, and small intestine of all drug-exposed animals failed to reveal signs of overt pathological changes, with the possible exception of an increase in the number of binuclear cells in the livers of DENSPM-treated transgenic animals. This occurred, however, in the absence of apparent necrosis or inflammation.
In an attempt to reduce mortality, animals were administered daily injections of DENSPM at a reduced dose level (125 mg/kg). Although this treatment was designed to last 5 days, the SSAT transgenic animals were again found to be more sensitive to the toxic effects of DENSPM. After the fourth injection, two of four animals died, and the experiment was terminated 24 h later. The causes of death were not obvious, and macroscopic examination revealed no signs of major organ involvement. A careful histological examination of liver, the tissue with the highest levels of SSAT activity, failed to reveal any overt pathological changes. There were, however, signs of gastrointestinal bleeding in the analog-treated transgenic animals but no obvious changes in mucosal histology. This 4-day treatment schedule gave rise to dramatic metabolic differences between the nontransgenic and transgenic animals (Table 1). As in the previous experiment, stimulation of liver or spleen SSAT activity in the nontransgenic animals in response to the treatment was not very impressive (1.5-fold in the liver, 2-fold in the spleen). Nonetheless, the treatment resulted in an obvious activation of polyamine catabolism, as indicated by the accumulation of putrescine and N1-acetylspermidine, and in decreases in the higher polyamine pools. A compensatory increase in ODC activity after the treatment was also obvious despite high tissue levels of analog. The analog seemed to have a dramatic effect on tissue polyamine metabolism in the transgenic animals. SSAT activity increased by a more than 800-fold in liver and nearly 40-fold in spleen. This was accompanied by almost complete disappearance in the liver of spermidine and spermine and a further increase in putrescine. Spermidine and spermine pools in the spleen were reduced to a lesser extent (Table 1). Because of the huge increase in liver SSAT activity, we again performed a Northern blot analysis of liver SSAT RNA. Unlike with the 24-h treatment, where there were only minor effects on the SSAT message (Fig. 1), the longer treatment resulted in a consistent 4-fold increase in the SSAT mRNA as shown in Fig. 2. This increase was limited to the mature message, as the larger transcript representing preprocessed hnRNA (Fogel-Petrovic et al. 1996
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
Transgenic animals have typically been used to probe gene function
in tissue development and oncogenesis. As shown in this study, they can
also be useful in defining the mode of drug action. The exaggerated
responses seen in transgenic animals displaying a tissue-wide
overexpression of the SSAT gene provides a system for identifying drugs
that either inhibit or activate polyamine catabolism and for defining
the metabolic and biologic consequences of this drug action. This
especially applies to the polyamine analogs, such as DENSPM, where
mounting experimental evidence indicates that induction of SSAT seems
to represent a major determinant of antitumor drug action in vivo
(Bernacki et al. 1995
). Thus, although analog suppression of polyamine
biosynthesis may contribute passively to polyamine depletion, it would
seem that, by increasing polyamine catabolism, SSAT plays the more
active role. The rapid depletion of intracellular polyamine pools may
also allow higher concentrations of the analog to accumulate in
tissues. As seen here, SSAT was potently induced, while the
characteristic down-regulation of key biosynthetic enzyme activities, a
response once thought to be critical to drug action (Porter and
Bergeron, 1988
), was not observed. Instead, ODC activity was actually
up-regulated, presumably in response to analog depletion of the natural
polyamines spermidine and spermine via SSAT induction. Why ODC was not
down-regulated by the massive amounts of analog present in the tissues
may be because the analog is somehow sequestered intracellularly and only able to interact at regulatory sites involved in SSAT induction. Sequestration might also account for the unexpectedly higher levels of
analog seen in transgenic tissues, although this could also be at least
partially due to depletion of spermidine and spermine pools.
It was also obvious that analog-mediated induction of SSAT could
enhance host toxicity. As has been reported (Casero et al. 1989
; Porter
et al. 1991
; Shappell et al. 1992
; Casero et al. 1992
), cell line
cytotoxicity by polyamine analogs in vitro appears to be closely linked
to induction of SSAT activity that is known to facilitate activation of
polyamine catabolism and/or excretion and the subsequent depletion of
spermidine and spermine pools (Seiler, 1987
). Whether oxidation of the
acetylated polyamines by polyamine oxidase is also related to the
cytotoxicity through oxidative stress is undetermined at the present
time and may, in fact, be cell-type dependent. In agreement with in
vitro studies (Casero et al. 1989
; Porter et al. 1991
; Shappell et al.
1992
), transgenic mice with highly inducible SSAT overexpression appear to be more sensitive to the toxic action of the polyamine analog, DENSPM. The modest induction of SSAT in tissues of nontransgenic animals is in accordance with earlier in vivo studies (Bernacki et al.
1995
). Although DENSPM is one of the most effective and best tolerated
compounds of the polyamine analog category (Bernacki et al. 1995
), the
drug caused a substantial mortality to the transgenic animals at dose
levels that were well below those that are well tolerated by normal
tumor-bearing mice (Bernacki et al. 1995
). A critical consideration
that still needs to be defined is whether the observed host toxicity is
related to antiproliferative effects as in cell culture or to various
other physiological responses mediated directly by the analog or
indirectly by polyamine depletion. In this regard it is significant to
note that, with the exception of the brain, all transgenic tissues
accumulated at least 2-fold more DENSPM than nontransgenic tissues.
Thus, the increased sensitivity of transgenic animals may be related to
more efficient tissue accumulation of the analog, which in turn could
bring about greater depletion of spermidine and/or spermine pools due
to greater SSAT expression. It should be noted, however, that
fibroblasts isolated from transgenic fetuses are much more sensitive to
growth inhibition by DENSPM than those from nontransgenic fetuses under
conditions where there is no significant difference in the amount of
intracellular analog (Alhonen et al. 1998
). This apparent paradox could
reflect basic differences between the role of SSAT in antiproliferative effects versus whole organ toxicities.
Earlier findings have indicated that substantial increases in SSAT
message achieved by transfection or drugs is only poorly translated in
the absence of exogenous polyamines (Fogel-Petrovic et al. 1996
) or
analogs (Parry et al. 1995a
). The induction of mammalian SSAT
expression is an extremely complex regulatory process that is known to
include transcriptional activation, stabilization of message, enhanced
translation, and prolongation of the enzyme protein half-life (Libby et
al. 1989
; Casero et al. 1990
; Porter et al. 1992
; Fogel-Petrovic et al.
1993
; Parry et al. 1995a
; Coleman et al. 1995
; Fogel-Petrovic et al.
1996
, 1997
). This multilevel enhancement of gene expression by DENSPM
results in a remarkable increase in enzyme activity in transgenic
animals that far exceeds the difference in gene copy number. Because
similar findings were obtained with metallothionein-driven SSAT
transgenic mice (S. Suppola, M. Pietilä, L. Alhonen, J. Jänne, unpublished data), the integration site is not
considered to be a factor.
The situation in the SSAT transgenic animals very much resembles the
findings obtained with cycloheximide treated (Fogel-Petrovic et al.
1996
) or transiently transfected cells (Parry et al. 1995a
). The amount
of SSAT-derived mRNA in the liver of transgenic animals was nearly 70 times higher than that found in the nontransgenic litter-mate (Fig. 2),
yet the actual enzyme activity was only marginally more than that seen
in the untreated transgenic liver (Table 2). Apparently, the large
amounts of SSAT message produced in transgenic tissues are not readily
translated, a process that seems to be activated by exposure to
exogenous polyamines (Fogel-Petrovic et al. 1996
) or, more efficiently,
by analogs as shown here and elsewhere (Fogel-Petrovic et al. 1996
,
Parry et al. 1995a
). The participation of analogs in this event is not
straightforward and appears, from the present study, to involve some
dose or time factor. A single injection of DENSPM produced an analog
level in the liver that was only 30 to 50% lower than that obtained after multiple administrations. This level increased SSAT activity by
approximately 10-fold and had little effect on the mRNA level. By
contrast, multiple injections increased analog level by 2-fold, raised
SSAT message level by about 4-fold, and massively enhanced enzyme
activity by approximately 800-fold. This would suggest that processes
related to message and protein accumulation may require threshold
levels of some additional component, possibly the SSAT protein itself.
The remarkable activation of SSAT gene expression obtained in response to DENSPM in the absence of down-regulation of biosynthetic enzymes provides the first definitive indication of the means by which this clinically-relevant analog depletes tissue polyamine pools in vivo. The data further emphasize the central role of SSAT in maintaining the homeostasis of the higher polyamines. Thus, these interesting mice will undoubtedly prove useful in identifying second generation analogs with reduced host toxicity and in determining the functional role of polyamines in the context of the whole animal.
| |
Acknowledgments |
|---|
We thank John Miller and Paula Diegelman for their skilled technical assistance. The also thank Barbara Holdridge for taking care of animal breeding.
| |
Footnotes |
|---|
Received September 30, 1998; Accepted December 18, 1998
1 Current Address: Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263. E-mail: porter{at}sc3101.med.buffalo.edu
This work was supported in part by the CA-65942 and CA-22153 US National Cancer Institute, National Institutes of Health, by the Academy of Finland and by Human Frontier Science Program.
Send reprint requests to: Dr. Carl W. Porter, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263. E-mail: porter{at}sc3101.med.buffalo.edu
| |
Abbreviations |
|---|
DENSPM, N1,N11-diethylnorspermine; SSAT, spermidine/spermine N1-acetyltransferase; ODC, ornithine decarboxylase; AdoMetDC, S-adenosylmethionine decarboxylase.
| |
References |
|---|
|
|
|---|
-difluoromethylornithine as chemopreventive agent: tolerance to daily oral administration in humans.
Cancer Epidemiol Biomarkers Prev
2:
243-247[Abstract].
-difluoromethyl-ornithine.
J Natl Cancer Inst
85:
732-737This article has been cited by other articles:
![]() |
C. Rodriguez-Caso, R. Montanez, M. Cascante, F. Sanchez-Jimenez, and M. A. Medina Mathematical Modeling of Polyamine Metabolism in Mammals J. Biol. Chem., August 4, 2006; 281(31): 21799 - 21812. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Niiranen, M. Pietila, T. J. Pirttila, A. Jarvinen, M. Halmekyto, V.-P. Korhonen, T. A. Keinanen, L. Alhonen, and J. Janne Targeted Disruption of Spermidine/Spermine N1-Acetyltransferase Gene in Mouse Embryonic Stem Cells. EFFECTS ON POLYAMINE HOMEOSTASIS AND SENSITIVITY TO POLYAMINE ANALOGUES J. Biol. Chem., July 5, 2002; 277(28): 25323 - 25328. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||